Clinical-Stage company Heptares Announces Positive Results from Early-Stage Dementia Trial

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for patients with cognitive impairment due to dementia and schizophrenia. During the Phase 1b study, 28 healthy elderly subjects were given different doses of HTL9936,  to test the effect of drug on measures of brain activity

Continue Reading

World’s Largest Dementia Study Launched in the UK

The Medical Research Council (MRC) has announced the launch of the world’s largest study into dementia, involving more than two million people.  The clinical study will be conducted through the Medical Research Council and industry partners. The UK Dementias Research Platform (UKDP) will investigate the causes of dementia across a range of different neurodegenerative conditions,

Continue Reading